The briefing
Clinical Lab Products reports a urine test outperformed PSA testing and MRI for monitoring low‑risk prostate cancer on active surveillance, reducing unnecessary biopsies by 64%. The findings suggest a less invasive pathway for many patients, pending broader validation and adoption.
Original headline
Urine Test Reduced Unnecessary Prostate Biopsies by 64%, Study Finds